The CHF supports the reintroduction of pills into the scope of the remade Order. The omission of these from the current Order is an unfortunate regulatory oversight. Consumers implicitly trust the regulatory system to ensure any product made available to them undergoes rigorous assessment of...
We expect the primary impact of the reclassification for consumers will be a greater level of quality for Active Medical Devices in terms of reliability, safety and effectiveness. By putting these medical devices into a higher class they will undergo more rigorous assessment prior to becoming...
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation has been formed with a patient-centred approach in mind.
CHF notes that this consultation’s scope is limited to the regulatory guidance in line with existing regulatory requirements, and not...
CHF appreciates the opportunity to provide a comment in response to proposed changes to a number of definitions and the scope of the medical device regulatory framework in Australia.
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation...
During 2019, the Therapeutic Goods Administration (TGA) will continue to implement changes in response to the Review of Medicines and Medical Devices Regulation (MMDR). This webinar aimed to update consumers on these medical device consultations and answer questions from consumers.
...
This position statement has been developed by the Consumers Health Forum of Australia (CHF) and the Centre for Health Policy, the University of Melbourne. It has been informed by the discussions at a Specialist Fee and Performance Transparency Roundtable held at the University of Melbourne on...
This submission is prepared in the context of an imminent federal election. CHF will be putting out an election priorities document which sets out our proposed agenda for health reform for through to 2025.